EUCTR2010-022505-18-GB进行中（未招募）1 期
A Phase II/III Open Label, Randomised Study of the Safety, Reactogenicity and Immunogenicity of a Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine (Menveo) or Glaxosmithkline Meningococcal ACWY Conjugate Vaccine in Adolescents Who Were Primed with Meningitec, Menjugate or Neisvac-C During Preschool Vaccination - PRIME
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 93
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •6.4.1 Inclusion Criteria • Previously enrolled on the Preschool Men C study conducted by NVEC in 1999/2000 • Participant (or if under 16 years of age, participant's parent or legally authorized representative) is willing and able to give written informed consent for own or child's participation after the nature of the study has been explained. • No contraindications to vaccination as specified in the Green Book”- Immunisation against Infectious Disease, HMSO. • Participant (if under 16 years of age) who gives informed written assent for participation in the study. • Vaccinated with Meningitec (MCC CRM) or Menjugate (MCC CRM) or NeisVac-C (MCC TT) between 3.5-6 years of age. • Known to be free of relevant medical problems as determined by a medical history and clinical assessment. • Where applicable, parent or legally authorised representative is willing to allow his or her child’s GP to be notified of participation in the study and contacted if required for confirmation of vaccination history.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •The participant may not enter the study if ANY of the following apply: • History of invasive meningococcal disease. • Have a history of household contact or intimate exposure to an individual with culture proven Neisseria meningitis disease in the previous 60 days. • Any vaccination against MenC disease since MCC vaccine given between 3.5 to 6 years. • Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection. • Major congenital defects or serious chronic disease including progressive neurological disease or seizure disorder. • Have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time. • Have a history of severe allergic reactions after previous vaccinations such as anaphylactic shock, asthma, urticaria, or other allergic reaction or hypersensitivity to any vaccine component. • Have received another investigational agent within 90 days or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another investigational trial through the end of the study. • In the event that administration of another licensed vaccine is needed during the study, this vaccine should not be administered within 30 days of any study injection according to investigator’s judgment (exception: licensed flu-vaccine should not be administered within 14 days of study vaccines). • Have received any blood or blood products within the past 12 weeks. • Have any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study. • Receipt of systemic antibiotics (either oral or parenteral) will delay enrolment until at least 7 days after cessation of antibiotics. The investigator can withdraw a subject from treatment if, in his or her clinical judgment, it is in the best interest of the subject. • Vaccination will be postponed until resolution of fever if axillary temperature is = 38 C. • For all visits, if allowed by the study visit window, receipt of systemic antibiotics (either oral or parental) will delay venepuncture until at least 7 days after cessation of antibiotics. • Female participants will be assessed for the need to perform a pregnancy test as per SOP CTSOP071 (Pregnancy Testing and Exclusion from Studies). If there is a possibility of being pregnant, a pregnancy test will be offered - in that case, participants who take up the test and are negative will be recruited.
研究者
相似试验
进行中（未招募）
1 期
An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy - N/ABreast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for further endocrine therapyMedDRA version: 9.1 Level: LLT Classification code 10027452 Term: Metastases to boneEUCTR2009-012189-30-GBAlgeta ASA
进行中（未招募）
1 期
An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy - N/AEUCTR2009-012189-30-BEAlgeta ASA20
进行中（未招募）
1 期
A study to look at how effective, how safe and how well tolerated a study drug called ISIS 702843 is when given under the skin to patients with Non-Transfusion Dependent ß-Thalassemia Intermedia. This study will also look at the movement of ISIS 702843 in the body and how ISIS 702843 affects the body.EUCTR2019-003505-96-GRIonis Pharmaceuticals, Inc.29
进行中（未招募）
1 期
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of sapablursen (ISIS 702843-CS4) Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)Polycythemia VeraCTIS2024-512482-14-00Ionis Pharmaceuticals Inc.60
尚未招募
2 期
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Patients with Non-Transfusion Dependent ß-Thalassemia IntermediaChronic anemia due to ineffective erythropoiesis (IE) in subjects with ß thalassemiathalassemiaLBCTR2020071296Ionis Pharmaceuticals, Inc.36